Current State of Anticoagulants to Treat Deep Venous Thrombosis
- 652 Downloads
Anticoagulation remains the cornerstone of treatment in patients with deep vein thrombosis (DVT). While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants have provided clinicians with an expanding set of therapeutic options for DVT. This review summarizes the pharmacology and clinical trial results of these new oral anticoagulants. Several practical considerations to the use of these oral anticoagulants including issues related to adherence, monitoring, and reversal are also discussed.
KeywordsDeep vein thrombosis Anticoagulants Rivaroxaban Dabigatran Apixaban Edoxaban Warfarin
This work was supported by the National Institutes of Health and the National Institute of Aging (K23HL092161 and R03AG040631 to M.T.R.). We thank Ms. Alex Greer for her excellent editorial assistance.
Compliance with Ethics Guidelines
Conflict of Interest
Timothy Vo declares that he has no conflict of interest.
Sara Vazquez declares that she has no conflict of interest.
Matthew T. Rondina has received honoraria from Boehringer Ingelheim for Advisory Board participation.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722–7. doi: 10.1111/j.1525-1497.2006.00458.x.PubMedCentralPubMedCrossRefGoogle Scholar
- 15.••Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S. doi: 10.1378/chest.11-2301. These evidence-based guidelines discuss the treatment of DVT..PubMedCentralPubMedGoogle Scholar
- 16.••Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016–23. doi: 10.1182/blood-2011-10-378950. This outstanding review highlights patient characteristics important to consider when choosing between new or established anticoagulants..PubMedCrossRefGoogle Scholar
- 17.Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British journal of clinical pharmacology. 2010;70(5):703–12. doi: 10.1111/j.1365-2125.2010.03753.x.PubMedCentralPubMedCrossRefGoogle Scholar
- 21.Schulman S, Kakkar AK, Schellong S, Goldhaber SZ, Henry E, Mismetti P et al., editors. A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Presented at the 53rd Annual American Society of Hematology Meeting; 2011.Google Scholar
- 26.Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287–94. doi: 10.1111/jth.12230.PubMedCrossRefGoogle Scholar
- 28.Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S–50S. doi: 10.1378/chest.11-2298.PubMedCentralPubMedGoogle Scholar
- 29.•Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245–52. doi: 10.1111/jth.12096. This review discussed important aspects of the laboratory assessment of novel oral anticoagulants..PubMedCrossRefGoogle Scholar
- 30.•Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141–5. doi: 10.1002/ajh.23202. This review discussed important aspects of the reversal of novel oral anticoagulants..PubMedCrossRefGoogle Scholar
- 32.Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G, et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013;11(1):177–9. doi: 10.1111/jth.12038.PubMedCrossRefGoogle Scholar
- 38.Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979–87. doi: 10.1111/j.1538-7836.2012.04866.x.PubMedCrossRefGoogle Scholar